FFS - based on your knowledge do you agree that OPT narrowed down the ph3 trials specifically for the best responder sub groups based on ph2b data therefore ph3 should overall be higher BCVA gain than 2b (vis a vis)? Thoughts?
Add to My Watchlist
What is My Watchlist?